Since we started this study, newer more potent MCL-1 specific inhibitors have been developed and advanced to clinical studies as cancer therapeutics, including S64315/MIK665 (a derivate of S63845), AMG 176, and AZD5991 (Fig. 5A-C) [16–18]. The gene discussed is MCL1; the disease is cancer.